Search
Pulmonx Corp
LUNGAdd to Watchlist
1.470USD
+0.170+13.08%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
62.09MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+13.08%
5 Days
+5.76%
1 Month
-7.55%
6 Months
-33.48%
Year to Date
-33.48%
1 Year
-45.35%
Key Figures
1.300Open
1.495High
357.38KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.86%Turnover Ratio
1.300Prev. Close
1.300Low
352.75KTurnover
LossP/E Static
1.13P/B
0.00%Div Yield TTM
-39.31%ROA
3.88052wk High
0.28Volume Ratio
-56.39MNet Profit
41.67MShares
-1.2916EPS TTM
0.27Beta
-86.22%ROE
1.13052wk Low
15.00%Amplitude
77.94%Gross Margin
62.09MMarket Cap
-3.56Reward/Risk
5.40%Risk Rate
TradingKey Stock Score of Pulmonx Corp
Currency: USD Updated: 2026-07-01Key Insights
Pulmonx Corp's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 102 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.40.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Pulmonx Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Pulmonx Corp Highlights
StrengthsRisks
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 31.78% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 90.50M.
Overvalued
The company’s latest PE is -1.14, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 36.92M shares, decreasing 13.38% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 83.73K shares of this stock.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
3.400
Target Price
+161.54%
Upside Space
Pulmonx Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Pulmonx Corp Info
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Ticker SymbolLUNG
CompanyPulmonx Corp
CEOFrench (Glendon E)
Websitehttps://pulmonx.com/
Related Instruments
+2.62%
+2.41%
+1.57%
+1.18%
+1.73%
+1.30%
-0.50%
+1.27%
+7.60%
+0.88%
+0.39%
+0.89%
+1.92%
+1.70%
+5.81%
+3.09%
+2.12%
+1.08%
+1.78%
+0.41%Popular Instruments
52385.200
+130.900 (+0.25%)
29775.200
-24.100 (-0.08%)
7486.800
+11.300 (+0.15%)
14797.000
-558.000 (-3.63%)
68944.000
-541.000 (-0.78%)
6328.900
+53.500 (+0.85%)
67.094
-0.874 (-1.29%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4065.590
+34.820 (+0.86%)
FAQs
What is the current price of Pulmonx Corp (LUNG)?
The current price of Pulmonx Corp (LUNG) is 1.47.
What is the symbol of Pulmonx Corp?
The ticker symbol of Pulmonx Corp is LUNG.
What is the 52-week high of Pulmonx Corp?
The 52-week high of Pulmonx Corp is 3.88.
What is the 52-week low of Pulmonx Corp?
The 52-week low of Pulmonx Corp is 1.13.
What is the market capitalization of Pulmonx Corp?
The market capitalization of Pulmonx Corp is 61.26M.
Is Pulmonx Corp (LUNG) currently rated as Buy, Hold, or Sell?
According to analysts, Pulmonx Corp (LUNG) has an overall rating of Buy, with a price target of 3.40.
What is the Earnings Per Share (EPS TTM) of Pulmonx Corp (LUNG)?
The Earnings Per Share (EPS TTM) of Pulmonx Corp (LUNG) is -1.33.